Subt. Form PTO-1449					Docket Number HYZ-479CP				Application Number		
INFORMATION DISCLOSURE IN AN APPLICATION					HYZ-479CP 7508.577)				09/965,116달		
IN AN APPLICATION			DEC 1	7 2001	35	~1	pplicant				
	(Use several sheet	essary)	λ -		Ĕ/	Kar	ndimalla				
				2 PENTE	- CONE	Filin	g Date	G	iroup Art Ur		
Sheet	1	OF		2	Ser	otemb	er 26, 200 <sup>-</sup>	1 /634	<del>5 1632 -</del>	- g [	
			L							18	
			U	.S. Pate	nt Do	cume	nts		FILING	_8	
EXAMINE INTÎAL	XAMINER DOCUMENT DATE		TE	NAM			CLASS	SUBCLASS		DATE OPRIATE	
1 14	5,149,798	09/2	22/92	Agrawal et al. 536				27			
				D-	1 1 D	\					
EVALUATE TO THE PARTY OF THE PA	D DOCUMENT	<del></del>	For	eign Pa	tent L	ocum	ents		TRANS	LATION	
EXAMINE INITIAL		DA	ATE .	C	OUNTR	1	CLASS	SUBCLASS	YES	NO	
			) II	D			A 11 . T'11	- D-4- D-4	D	[4-\]	
1 12	1. Khorana et al. (1						g Author, Titl	e, Date Perti	nent Pag	es, Etc.)	
C//4	Reese (1978) "T	he Chem	ical Syntl	hesis of Oli	go- and F	Poly-Nucl	eotides By The	Phosporotrieste	r Approach	33	
	Reguege et al	3143-317 (1981) "D	eoxynuc	leoside Pho	sphoram	idites - /	A New Class of	Kev Intermediat	es for		
C	/ <sup>3.</sup> U Deoxypolynucled	tide Synt	hesis." 7	Tetrahedron	Lett. 22:	1859-186	52				
C4. Connolly et al. (1984) "Synthesis and Characterization of an Octanucleotide Containing the EcoRl Recognition Sequence With A Phosphorothioate Group At The Cleavage Site," Biochemistry 23:3443											
Agrawal et al. (1987) "Oligodeoxynucleotise Methylphosphonates: Synthesis and Enzymic Degradation,"											
	C5.   Tetrahedron Lett. 28(31):3539-3542  C6. Jager et al. (1988) Oligonucleotide N-Alkylphosphoroamidates: Synthesis and Binding to Polynucleotides,"  Biochemistry 27:7237										
	Agrawal et al. (1	988) "Olig						othioates As Inh	ibitors of H	ıman	
<del></del>	Zon et al. (1991)	cy Virus, "Phosph	<i>Proc. Na</i> orothioat	<i>tl. Acad. Sc.</i> te Oligoncul	i. USA 85 eotides"	0:7079-70 Oligonuc	083 eleotides and An	alogues: A Prac	ctical Approx	ach pp.	
C8. Zon et al. (1991) "Phosphorothioate Oligonculeotides" Oligonucleotides and Analogues: A Practical Approach pp. 87-108											
	C9. Kuramoto et al. (1992) "Oligonucleotide Sequences Required For Natural Killer Cell Activation," <i>Jpn. J. Cancer Res.</i> 83:1128-1131										
	G10 Grooke (1993) "An Overview of Progress in Antisense Therapeutics," 8 Antisense & Nucl. Acid Drug Dev. 115-122										
CHC Press, Boca Haton, Florida							89				
C12. Pisetsky et al. (1994)"Stimulation of Murine Lymphocyte Proliferation By A Phosphorothioate Oligonucleotide With Antisense Activity For Herpes Simplex Virus," 54 Life Sci. 101							de With				
Yamamoto et al. (1994) "Lipofection of Synthetic Oligodeoxyribonucleotide Having a Palindromic Sequence of C13. AACGTT to Murine Spenocytes Enhances Interferon Production and Natural Killer Activity," 38 Microbiol. Immunol.											
831  (Agrave) et al. (1995) "Modified Oligopucleotides as Therapeutic and Diagnostic Agents." Curr Onin Biotechnol. 6:12-											
C15. Krieg et al. (1995) "CpG Motifs In Bacterial DNA Trigger Direct B-Cell Activation," Nature 371:546-549  Klinman et al. (1996) "CpG Motifs Present in Bacterial DNA Rapidly Induce Lymphocytes to Secrete Interleukin 6,											
Interleukin 12, and Interferon γ," 93 <i>Proc. Natl. Acad. Sci. USA</i> 2879											
	98:1119-1129  C18 , Zhao et al. (1996) "Effect of Different Chemically Modified Oligodeoxynucleotides on Immune Stimulation," Biochem.							Biochem.			
1 m	C19. Pharm. 51:173- Chu et al. (1997 Exp. Med. 1623	) "CpG O	ligodeox	ynucleotide	s Act As	Adjuvant	s That Switch O	n T Helper 1 (T	h1) Immunii	y," 186 <i>J</i> .	
DATE CONCIDEDED											
AAMINE	·	4 J_	0.	- FON			9-2	-03			

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

Subt	Form Di	O-1449	9_						_	
Subi.	ronn Pi	10-1449					cket Numbe	-		on Number
	INFO	DRMATION	DISCLO	SURE	TP		Z-479C		09/9	65,116
		IN AN APPL			(O')	- ~ A	508.577			<u>\</u>
				~ 1		<b>2</b> /		Applio		6
	(Us	se several shee	ets if nece	essarv	DEC 1	7 2001 by		Kandir	nalla	2 0
	•			1	_	<del>[</del> ]_				<b>F</b>
She	eet	2	OF		CEL .		iling Date		1.	Art Unit
			0,		1	ptem	ber 26,	2001	1635#	<del>332</del> 8 5
	X	Dunford et al. (1	997) "Antis	ansa 07· T	argoting	ho Mologulos	Dania of Di	7 (21 /		
H	C20.	7 7.03//aci, pp. 40								$\simeq$
9	C21.	Sparwasser et a Mediated Shock	l. (1997) "N	Macrophage	es Sense	Pathogens Vi	a DNA Moti	fs: Induction	of Tumor Necr	osis Factor-α-
	C22.	Zhao et al. (199)	7) "Pattern	and Kinetic	s of Cyto	kine Productio	n Following	Administra	tion of Phospho	rothioate
$\vdash\vdash$		1 Ongoniuologiages	) III IVIICE. /	Alluseuse	I IVIII:IHII:	ACIO LIDIO LIA	n/ Aus			
Ц	C23.	McCluskie et al. Responses Agai	nsi nebalii	is is Sunac	e Antider	i With Intranac	al Administr	ration to Mic	0 "	404.4400 4400
	C24.	Moldoveanu et a Influenza Virus,"	u. (1990) C	PUG DINA,	a novei ii	nmune Enhan	cer for Syst	temic and M	lucosal Immuniz	ation With
	C25.	Sparwasser et a	I. (1998) "B	acterial DN	A and Im	munostimulat	ory CnG Oli	gonucleotid	les Trigger Metu	tration and
H	C26,	_ Activation of Iviu	iiiie Deliali	uc cens. 7	28 Eur. J.	IMMUNOL 204	5			
<del>                                     </del>	<i>\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\</i>	Zhao et al. (1999)	(1999) "Hov	W BCG Lec	to the D	scovery of Imi	munostimula	atory DNA,"	52 Jap. J. Infed	t. Dis. 1
	C27.	i wouldles its iii	munosumu	IBIOIV ACIII	IITV " BIOO	ra X Med Ch	om Lott 0.	2152 2150		
一	C28.	Agrawal et al. (2) Today 72	000) "Antise	ense Thera	apeutics: I	s It As Simple	As Comple	mentary Ba	se Recognition,	" 6 Mol. Med.
1 Z	C29.	Zhao et al. (2000	) "Immuno	stimulatory	Activity of	f CpG Contair	ning Phosph	norothioate	Oligodeoxynucle	eotide is
Y		Modulated by Mo	odification o	of a Single	Deoxynuc	leoside," <i>Bioc</i>	org. & Med.	Chem. Lett.	10:1051-1054	
					<del></del>					
	_				-					
									<del> </del>	
					_					
			·			· · · · · · · · · · · · · · · · · · ·				
							_			
						<del></del>				
					-					
								<del></del>		
	$\Box$									
EXAMIN	EXAMINER DATE CONSIDERED									
	/	last		$\mathcal{L}$	_ /		0-2-	·^2		İ
ΕΥΛΝ		Initial if all all all all all all all all all al	The	D-10	10		13	U)		
if not cor	nforman	Initial if citation is consider	considered, ered/includ	Whether o	r not citat	on is in confor	mance with	MPEP § 6	09: Draw Line th	rough citation
				- copy will	. HOAL COI	minumication (	σαρμιισαπί.			

	,	QUE JOE MAN					_1_OF_1_			
Subt. Form PT	C-1449	(B) (E)		Dücket Number		Application N				
SUPP	LEMENTA	LINGERMAT	ION	FYB-C05US2		09/965,116				
DISCLO	DSURE IN	AN APPLICA	ſΙΟί√	Applicant						
// /-	- aguaral ab	eets if necessary	۱ ۱	Kandimalla et al.						
(US	e severai sii	eels II ; lecessal y	'	Filing Date		Group Art Unit				
<u> </u>				9/26/01 -1632 /635			-1635			
	*			NT DOCUMENTS						
EXAMINER INITIAL	IDENTIFIER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
		-			,	.1				
						RECE	NED			
						RECE	8 5005			
						1	10 /////			
						000	00000			
							TER 1600/2300			
						TECH CE	WTER 1600/2900			
		FOR	EIGN PA	TENT DOCUMEN	NTS	150.				
EXAMINER	IDENTIFIER	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION			
INITIAL		NUMBER					YES NO			
			<u> </u>							
	<u> </u>									
			<del> </del>							
			<del>                                     </del>							
	ОТН	ER DOCUMENTS	Including	Author, Title, Date,	Pertinent Pa	iges, Etc.)				
EXAMINER INITIAL	IDENTIFIER									
	C1	Agrawal et al., "Ar	tisense The	erapeutics", Curr. Op	in. Chem. B	ol., <b>2:</b> 519-528,	1998.			
	C2	Chaix et al., "3'-3' Linkied Oligonucleotides: Synthesis and Stability Studies", Bioorganic &								
		Medicinal Chemis	try Letters,	6:827-832, 1996.	CaC Castair	ing Oligodocy	vnucleotides"			
* .	C3	Klinman, Dennis M., "Therapeutic Applications of CpG-Containing Oligodeoxynucleotides",  Antisense & Nucleic Acid Drug Development, 8:181-184, 1998.								

EXAMINER	IDENTIFIER	
INITIAL		Agrawal et al., "Antisense Therapeutics", Curr. Opin. Chem. Biol., 2:519-528, 1998.
H	C1	Agrawal et al., Artiserise Trierapeutics, Curr. Opin. Crem. Diol., 2015-029, 1996.
	C2	Chaix et al., "3'-3' Linkied Oligonucleotides: Synthesis and Stability Studies", Bioorganic &
		Medicinal Chemistry Letters, 6:827-832, 1996.
40.	C3	Klinman, Dennis M., "Therapeutic Applications of CpG-Containing Oligodeoxynucleotides",
		Antisense & Nucleic Acid Drug Development, 8:181-184, 1998.
	C4	Yu et al. "Accessible 5'-End of CpG-Containing Phosphorothioate Oligodeoxynucleotides is
	04	Essential for Immunostimulatory Activity", Bioorganic & Medicinal Chemistry Letters, 10:2585-
		2588, 2000.
		Kandimalla et al., "Effect of Chemical Modifications of Cytosine and Guanine in a CpG-Motif of
	C5	Randimalia et al., Elect of Chemical Modifications of Cytosine and Cutaline in a Cytosine and Cy
,		Oligonucleotides: Structure-Immunostimulatory Activity Relationships", Bioorganic & Medicinal
1 1		Chemistry, 9:807-813, 2001.
1	C6	International Search Report in connection with Patent Cooperation Treaty Application
\ ( <i>f</i> h.		No. PCT/US01/30137.
<del></del>		
	ļ	
		*
		5
<u> </u>		
<b></b>	<del> </del>	
	-	
1	1	

foret f. Gyps- Ford 9-2-03